Tirzepatide is the international non-proprietary name (INN) of the active substance in MOUNJARO, and MOUNJARO is the proprietary brand name Eli Lilly uses for this medicine across applicable markets and strengths.[4] The two names refer to the same molecule, but they are not interchangeable regulatory terms across all jurisdictions: in the U.S., for example, tirzepatide is marketed as MOUNJARO for type 2 diabetes and as Zepbound for chronic weight management two distinct brands sharing the same active substance.[4] In the EU and certain other international markets, MOUNJARO covers both indications under a single brand.[3] MOUNJARO is the first approved dual GIP and GLP-1 receptor agonist in clinical use, distinguished from conventional single-axis GLP-1 receptor agonists by its simultaneous engagement of both incretin receptor pathways.[4] The 7.5mg strength occupies the intermediate position in the titration schedule, introduced after the patient has been on the 5mg dose for a minimum of four weeks.[3][4] In the KwikPen presentation, each multi-dose pre-filled pen contains 30mg of tirzepatide in 2.4ml of solution (12.5mg/ml), delivering four fixed doses of 7.5mg per 0.6ml subcutaneous injection for single-patient use.[3][5] This contrasts with the single-dose pre-filled pen presentation, in which the same 7.5mg strength is supplied in 0.5ml (15mg/ml) for one injection per pen
Puede provocar desde nuseas hasta vmitos, calambres abdominales o diarrea, dolores de cabeza, disfuncin heptica y renal, y un fuerte olor corporal
We hope the gentleman who suffered a medical incident today is okay," the statement read
World J Surg 35:78-84
